This company has been acquired
HSKA Stock Overview
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Heska Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$119.99 |
52 Week High | US$120.03 |
52 Week Low | US$57.83 |
Beta | 1.58 |
1 Month Change | 2.58% |
3 Month Change | 33.75% |
1 Year Change | 39.93% |
3 Year Change | 34.49% |
5 Year Change | 13.65% |
Change since IPO | 39.12% |
Recent News & Updates
Recent updates
Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?
Feb 09Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 50%?
Jan 18Heska to acquire LightDeck Diagnostics for $38.7M
Sep 12Is Heska (NASDAQ:HSKA) A Risky Investment?
Sep 07Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 31%?
Aug 17Heska Non-GAAP EPS of $0.34 misses by $0.03, revenue of $64.7M misses by $3.76M
Aug 08Is Heska (NASDAQ:HSKA) A Risky Investment?
May 09Heska Corporation (NASDAQ:HSKA) Shares Could Be 50% Below Their Intrinsic Value Estimate
Apr 03What Is Heska Corporation's (NASDAQ:HSKA) Share Price Doing?
Mar 02Heska (NASDAQ:HSKA) Has A Rock Solid Balance Sheet
Jan 09Estimating The Fair Value Of Heska Corporation (NASDAQ:HSKA)
Dec 13What Does Heska Corporation's (NASDAQ:HSKA) Share Price Indicate?
Nov 17Is Heska (NASDAQ:HSKA) A Risky Investment?
Sep 28Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?
Jul 21Is Heska (NASDAQ:HSKA) A Risky Investment?
Jun 29Calculating The Intrinsic Value Of Heska Corporation (NASDAQ:HSKA)
May 28Heska EPS beats by $0.69, beats on revenue
May 06Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?
Apr 15How Much Are Heska Corporation (NASDAQ:HSKA) Insiders Taking Off The Table?
Mar 19A Look At The Fair Value Of Heska Corporation (NASDAQ:HSKA)
Feb 21Shareholder Returns
HSKA | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.1% | 0.5% | -0.6% |
1Y | 39.9% | 3.0% | 21.7% |
Return vs Industry: HSKA exceeded the US Medical Equipment industry which returned 16.3% over the past year.
Return vs Market: HSKA exceeded the US Market which returned 15.1% over the past year.
Price Volatility
HSKA volatility | |
---|---|
HSKA Average Weekly Movement | 6.3% |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HSKA's share price has been volatile over the past 3 months.
Volatility Over Time: HSKA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 808 | Kevin Wilson | www.heska.com |
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops.
Heska Corporation Fundamentals Summary
HSKA fundamental statistics | |
---|---|
Market cap | US$1.31b |
Earnings (TTM) | -US$20.03m |
Revenue (TTM) | US$254.89m |
5.1x
P/S Ratio-65.4x
P/E RatioIs HSKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HSKA income statement (TTM) | |
---|---|
Revenue | US$254.89m |
Cost of Revenue | US$145.47m |
Gross Profit | US$109.42m |
Other Expenses | US$129.45m |
Earnings | -US$20.03m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.84 |
Gross Margin | 42.93% |
Net Profit Margin | -7.86% |
Debt/Equity Ratio | 22.9% |
How did HSKA perform over the long term?
See historical performance and comparison